BRPI0719912A2 - Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico - Google Patents

Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico

Info

Publication number
BRPI0719912A2
BRPI0719912A2 BRPI0719912-0A2A BRPI0719912A BRPI0719912A2 BR PI0719912 A2 BRPI0719912 A2 BR PI0719912A2 BR PI0719912 A BRPI0719912 A BR PI0719912A BR PI0719912 A2 BRPI0719912 A2 BR PI0719912A2
Authority
BR
Brazil
Prior art keywords
systemic lupus
lupus erythematosis
disease
reducing passenger
treating
Prior art date
Application number
BRPI0719912-0A2A
Other languages
English (en)
Inventor
Barbara White
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BRPI0719912A2 publication Critical patent/BRPI0719912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
BRPI0719912-0A2A 2006-12-06 2007-12-06 Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico BRPI0719912A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US87300806P 2006-12-06 2006-12-06
US90776707P 2007-04-16 2007-04-16
US90776207P 2007-04-16 2007-04-16
US92422007P 2007-05-03 2007-05-03
US92421907P 2007-05-03 2007-05-03
US92458407P 2007-05-21 2007-05-21
US96018707P 2007-09-19 2007-09-19
US99617607P 2007-11-05 2007-11-05
US99617407P 2007-11-05 2007-11-05
US99621907P 2007-11-06 2007-11-06
US99682007P 2007-12-06 2007-12-06
PCT/US2007/024941 WO2008070135A2 (en) 2006-12-06 2007-12-06 Methods of treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
BRPI0719912A2 true BRPI0719912A2 (pt) 2014-03-04

Family

ID=39492862

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0719912-0A2A BRPI0719912A2 (pt) 2006-12-06 2007-12-06 Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
BRPI0720035-8A BRPI0720035A2 (pt) 2006-12-06 2007-12-06 métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0720035-8A BRPI0720035A2 (pt) 2006-12-06 2007-12-06 métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit

Country Status (10)

Country Link
US (5) US20100143373A1 (pt)
EP (3) EP2073844A4 (pt)
JP (4) JP2010512313A (pt)
KR (2) KR101532797B1 (pt)
AU (2) AU2007327993B2 (pt)
BR (2) BRPI0719912A2 (pt)
CA (2) CA2670594A1 (pt)
MX (1) MX2009005787A (pt)
RU (2) RU2527068C2 (pt)
WO (2) WO2008070137A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073844A4 (en) * 2006-12-06 2011-06-01 Medimmune Llc METHOD FOR TREATING SYSTEMIC LUPUS ERYTHEMATODES
JP2010526107A (ja) * 2007-05-03 2010-07-29 メディミューン，エルエルシー 自己免疫疾患の自己抗体マーカー
EP2666874B1 (en) * 2007-07-12 2015-05-27 The Brigham and Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
BRPI0908065A2 (pt) * 2008-02-08 2015-08-11 Medimmune Llc Métodos para tratar um paciente que possui um ifn do tipo i ou doença ou distúrbio mediado por ifnalfa, para neutralizar um perfil de marcador mirna diferencialmente regulado em um paciente, para monitorar ou prognosticar uma progressão da doença inflamatória e da doença miosite de um paciente, para monitorar a progressão da doença inflamatória ou autoimune e da doença miosite de um paciente e para tratar um paciente com miosite
ES2613055T3 (es) * 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
CA2796666C (en) 2010-04-21 2020-04-14 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CA2822639A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
AU2013204776A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
GB201115665D0 (en) * 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US9726668B2 (en) 2012-02-09 2017-08-08 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US20150168398A1 (en) 2012-05-17 2015-06-18 The Johns Hopkins University Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy
WO2013188494A1 (en) * 2012-06-13 2013-12-19 Medimmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
US20140039907A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for collecting patient data with a portable electronic device
US20140156297A1 (en) * 2012-08-03 2014-06-05 Axelacare Holdings, Inc. Computer program, method, and system for pharmacist-assisted treatment of patients
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
AU2015302870B2 (en) 2014-08-14 2021-12-23 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
CN105420347A (zh) * 2014-08-21 2016-03-23 南京大学医学院附属鼓楼医院 一种用于系统性红斑狼疮的基因诊断试剂盒
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
CN109804245B (zh) 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
EP3519833B1 (en) 2016-09-29 2024-08-14 MeMed Diagnostics Ltd. Methods of prognosis and treatment
CN110073220A (zh) 2016-09-29 2019-07-30 米密德诊断学有限公司 风险评估和疾病分类的方法
WO2018112464A1 (en) * 2016-12-16 2018-06-21 The Penn State Research Foundation Methods for improved reproductive management of ruminant ungulates
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113692287A (zh) * 2018-10-26 2021-11-23 詹森生物科技公司 I型干扰素标记及使用方法
KR20210100115A (ko) 2018-12-03 2021-08-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 올리고-벤즈아미드 유사체 및 암 치료에서의 이의 용도
CN113508138B (zh) 2019-02-15 2024-08-09 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍
KR102429261B1 (ko) 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커
TW202228705A (zh) * 2020-10-02 2022-08-01 美商西建公司 治療全身性紅斑性狼瘡之方法及生物標記作為對療法之臨床敏感性之預測子之用途
PT4114465T (pt) 2021-04-23 2023-11-03 Astrazeneca Ab Regime de dosagem de anti-ifnar1 para injeção subcutânea
CA3223192A1 (en) 2021-06-18 2022-12-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
FR3138815A1 (fr) * 2022-08-12 2024-02-16 bioMérieux Détermination de la nature virale ou bactérienne d’une infection
CN117305441B (zh) * 2023-10-13 2025-04-08 福建农林大学 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FR2692168B1 (fr) 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5877302A (en) 1994-03-23 1999-03-02 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6905587B2 (en) * 1996-03-22 2005-06-14 Ronald Redline Method for enhancing the solderability of a surface
JP2002506436A (ja) 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
CA2467647A1 (en) * 2001-11-30 2003-06-05 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
ATE477000T1 (de) * 2002-11-21 2010-08-15 Bayhill Therapeutics Inc Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
KR101225299B1 (ko) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
EP2662390B1 (en) * 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US7833795B2 (en) * 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
US7571055B2 (en) * 2004-10-13 2009-08-04 Regents Of The University Of Minnesota Systemic lupus erythematosus
WO2008021976A2 (en) * 2006-08-09 2008-02-21 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
MX2007009466A (es) * 2005-02-10 2007-12-07 Baylor Res Inst Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.
US20070117105A1 (en) * 2005-05-12 2007-05-24 Crow Mary K Interferon assay
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
DK2327792T3 (da) * 2005-08-05 2014-01-13 Genentech Inc Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP2073844A4 (en) * 2006-12-06 2011-06-01 Medimmune Llc METHOD FOR TREATING SYSTEMIC LUPUS ERYTHEMATODES
BRPI0809674A2 (pt) * 2007-03-30 2014-10-07 Medimmune Llc Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5
ES2613055T3 (es) * 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1

Also Published As

Publication number Publication date
EP2073844A4 (en) 2011-06-01
US20100143372A1 (en) 2010-06-10
KR20090088932A (ko) 2009-08-20
EP2077858A4 (en) 2011-07-20
EP2073844A2 (en) 2009-07-01
EP2712930A2 (en) 2014-04-02
WO2008070137A3 (en) 2008-11-20
CA2670897A1 (en) 2008-06-12
RU2014127178A (ru) 2016-01-27
WO2008070135A3 (en) 2008-11-27
RU2527068C2 (ru) 2014-08-27
US20170121771A1 (en) 2017-05-04
KR101532797B1 (ko) 2015-07-01
JP2010512315A (ja) 2010-04-22
MX2009005787A (es) 2009-06-08
WO2008070137A2 (en) 2008-06-12
CA2670594A1 (en) 2008-06-12
JP2014014370A (ja) 2014-01-30
RU2009125616A (ru) 2011-07-27
KR20090088931A (ko) 2009-08-20
AU2007327995A1 (en) 2008-06-12
AU2007327993B2 (en) 2013-06-20
EP2712930A3 (en) 2014-04-23
WO2008070135A2 (en) 2008-06-12
WO2008070135A8 (en) 2009-12-17
US20100143373A1 (en) 2010-06-10
JP2010512313A (ja) 2010-04-22
AU2007327995B2 (en) 2013-10-10
JP2014040430A (ja) 2014-03-06
US20150147336A1 (en) 2015-05-28
US20150044222A1 (en) 2015-02-12
EP2077858A2 (en) 2009-07-15
AU2007327993A1 (en) 2008-06-12
BRPI0720035A2 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
BRPI0719912A2 (pt) Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
PT2178796T (pt) Método contínuo para tratamento de líquidos e fabrico de certos constituintes
BRPI0817664A2 (pt) Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0817292A2 (pt) Método e aparelho para completação de poços.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0814776A2 (pt) Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
BRPI0812448A2 (pt) Método para aperfeiçoamento de propriedades de proteína
BRPI0923695A2 (pt) agente de tratamento de superfície para chapas de aço galvanizadas, chapas de aço galvanizadas e método para produção destas
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0818765A2 (pt) Anti-pcsk9 e método para tratar distúrbios de lipídio e colesterol.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0809690A2 (pt) Composição de lubrificante, e, método
BRPI0720232A2 (pt) Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona
BRPI0719838A2 (pt) Método e aparelho para identificar regiões faciais
BRPI0822175A2 (pt) Método e aparelho para explosão de pequena carga.
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0812249A2 (pt) Aparelho para o controle de frenagem automotiva e método do mesmo
BRPI0817328A2 (pt) Método e aparelho para tratamento de resíduo orgânico.
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]